



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
INVESTMENT MANAGEMENT

October 30, 2014

Eric F. Fess, Esq.
Chapman and Cutler LLP
111 West Monroe Street
Chicago, Illinois 60603

Re: Guggenheim Defined Portfolios, Series 1250
File Nos. 333-199157 and 811-03763

Dear Mr. Fess:

On October 3, 2014, you filed a registration statement on Form S-6 for Guggenheim Defined Portfolios, Series 1250 (the "Fund"), consisting of a unit investment trust, BofA Merrill Lynch Health & Wellness Portfolio, Series 1 (the "trust"). We have reviewed the registration statement, and have provided our comments below. For convenience, we generally organized our comments using headings and defined terms from the registration statement. Where a comment is made in one location, it is applicable to all similar disclosure appearing elsewhere in the registration statement.

PROSPECTUS

Investment Summary — Principal Investment Strategy

1. Since the name of the trust includes the term "health & wellness," please provide a policy to invest at least 80% of the value of the trust's assets in the health and wellness industries, and provide the specific criteria the trust uses to determine that a company is in the health and wellness industries. See Rule 35d-1(a)(2)(i) under the Investment Company Act of 1940. For example, the trust might consider a company to be part of the health and wellness industries if it derives 50% or more of its profits or revenues from the health and wellness industries, or has 50% or more of its assets committed to these industries. Additionally, the first sentence in this section states that the trust will invest in 30 companies "spread across various sectors and industries." Please revise this sentence to more accurately describe the trust's emphasis on the health and wellness industries.

Investment Summary — Principal Risks

2. The fifth bullet point in this section states that the trust invests in ADRs and a CDI. Please disclose in the discussion of the trust's principal investment strategy that the trust invests in these investment vehicles, and provide definitions for both ADRs and CDIs.

GENERAL COMMENTS

3. We note that portions of the filing are incomplete. We may have additional comments on such portions when you complete them in pre-effective amendments, on disclosures made in response to this letter, on information you supply to us, or on exhibits added in any pre-effective amendments.

4. Responses to this letter should be in the form of a pre-effective amendment filed pursuant to Rule 472 under the Securities Act of 1933. Where no change will be made in the filing in response to a comment, please indicate this fact in a letter to us and briefly state the basis for your position.

5. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing reviewed by the staff to be certain that they have provided all information investors require to make an informed decision. Since the Fund and its sponsor are in possession of all facts relating to the Fund's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

* * * * *

Notwithstanding our comments, in the event the Fund requests acceleration of the effective date of the pending registration statement, it should furnish a letter, at the time of such request, acknowledging that

- should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
- the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Fund from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
- the Fund may not assert this action as a defense in any proceeding initiated by the Commission or any person under federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Investment Management in connection with our review of your filing or in response to our comments on your filing.

Eric F. Fess, Esq.
October 30, 2014
Page 3

We will consider a written request for acceleration of the effective date of the registration statement as a confirmation of the fact that those requesting acceleration are aware of their respective responsibilities. We will act on the request and, pursuant to delegated authority, grant acceleration of the effective date.

Should you have any questions prior to filing a pre-effective amendment, please feel free to contact me at 202-551-6959.

Sincerely,

/s/ Edward P. Bartz

Edward P. Bartz
Senior Counsel